Drugs

UK & Wales: NICE Recommends First Treatment In Two Decades For Sickle Cell Disease
Clinical News

UK & Wales: NICE Recommends First Treatment In Two Decades For Sickle Cell Disease

For the first time in 20 years, a new therapy for sickle cell disease is to be made available on the UK National Health Service (NHS). Crizanlizumab (Adakveo) by Novartis…
Clinical Trials Update: The June 2021 Edition
Clinical News

Clinical Trials Update: The June 2021 Edition

TIF provides you with comprehensive and up-to-date information on developing drugs and therapies for thalassaemia and sickle cell disease (SCD) currently in clinical trials. Our most recent June 2021 update…
MONTHLY UPDATE: COVID-19 Developing Vaccinations & Therapeutic Drugs
Publications

MONTHLY UPDATE: COVID-19 Developing Vaccinations & Therapeutic Drugs

All the latest updates of TIF’s Vaccinations & Therapeutic Drugs Guide for COVID-19 gathered in one single document. English
TIF’s Point of View: Medicines Regulatory Systems – Continued Strengthening Is Required
News

TIF’s Point of View: Medicines Regulatory Systems – Continued Strengthening Is Required

Access to quality-assured medical products improves health and saves lives. Nevertheless, one third of the world’s population lacks timely access to quality-assured medicines while estimates indicate that at least 10%…
TIF Supports IAPO´s Call For The Ratification Of The African Medicines Agency Treaty
Member News

TIF Supports IAPO´s Call For The Ratification Of The African Medicines Agency Treaty

Two years after the Treaty to establish an African Medicines Agency was agreed, over 40 leading organizations, including the Thalassaemia International Federation (TIF), and hundreds of thousands of patients, researchers…
TIF Updated Vaccinations & Therapeutic Drugs COVID-19 Guide Has Landed
News

TIF Updated Vaccinations & Therapeutic Drugs COVID-19 Guide Has Landed

A comprehensive Guide for both existing and developing vaccines and treatments against COVID-19, exclusively developed by TIF for its global thalassaemia community. Featuring: Pfizer, Moderna, AstraZeneca: What are the differencies…
Roche and Atea Pharmaceuticals Link Up To Co-Develop Remdesivir Rival Drug For COVID-19
Clinical News

Roche and Atea Pharmaceuticals Link Up To Co-Develop Remdesivir Rival Drug For COVID-19

The two companies will jointly develop, manufacture and distribute AT-527, Atea’s investigational oral antiviral for the potential treatment of COVID-19. According to Roche, AT-527 blocks the viral RNA polymerase enzyme…
TIF Participates in EMA’s Annual Training Day 2020
News

TIF Participates in EMA’s Annual Training Day 2020

TIF has participated in the Annual Training Day of the European Medicines Agency (EMA), held on 23 October 2020. TIF participants, Ms Lily Cannon (TIF Operations Manager) and Ms Eleni…
Imara Announces First Patient Dosed in Forte Phase 2b Clinical Trial of IMR-687 in β-Thalassaemia
Clinical News

Imara Announces First Patient Dosed in Forte Phase 2b Clinical Trial of IMR-687 in β-Thalassaemia

Imara Inc., a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of haemoglobin,  announced dosing of the first patient…
FDA Approves New Formulation for Ferriprox (Deferiprone) Twice-a-Day Tablets
Clinical News

FDA Approves New Formulation for Ferriprox (Deferiprone) Twice-a-Day Tablets

Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., today announced that the U.S. Food and Drug Administration (FDA) has approved Ferriprox® (deferiprone) twice-a-day tablets for the treatment…
Back to top button